- Trials with a EudraCT protocol (19)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
19 result(s) found for: CYP2C9.
Displaying page 1 of 1.
EudraCT Number: 2008-006451-52 | Sponsor Protocol Number: 4474 | Start Date*: 2009-01-27 | |||||||||||
Sponsor Name:Newcastle upon Tyne Hospitals NHS Foundation Trust | |||||||||||||
Full Title: An investigation of the association between vitamin K intake, vitamin K epoxide reductase subunit (VKORC1) genotype and anticoagulation response to warfarin | |||||||||||||
Medical condition: Patients will be recruited who are receiving long term warfarin therapy for the treatment or prevention of venous or arterial thrombosis or embolism | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-004044-28 | Sponsor Protocol Number: AKF-396 | Start Date*: 2020-12-18 | |||||||||||
Sponsor Name:University of Southern Denmark | |||||||||||||
Full Title: Flucloxacillin as an inducer of CYP-enzymes | |||||||||||||
Medical condition: Healthy volunteers. (Flucloxacillin is used against infections caused by beta-lactamase-producing organisms) Testing for drug-drug interactions caused by flucloxacillin | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-001462-81 | Sponsor Protocol Number: FARM7KP2PX | Start Date*: 2008-10-27 | |||||||||||
Sponsor Name:OSPEDALE POLICLINICO S. MATTEO | |||||||||||||
Full Title: Effects of Losartan versus Nebivolol versus the association of both on the progression of aortic root dilation in Marfan Syndrome (MFS) with FBN1 gene mutations | |||||||||||||
Medical condition: Marfan Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-003502-28 | Sponsor Protocol Number: AP-325.04 | Start Date*: 2020-02-14 | |||||||||||
Sponsor Name:Algiax Pharmaceuticals GmbH | |||||||||||||
Full Title: A Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of AP-325 in Subjects with Peripheral Post-surgical Neuropathic Pain | |||||||||||||
Medical condition: Peripheral post-surgical neuropathic pain | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) CZ (Completed) ES (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-004578-15 | Sponsor Protocol Number: 01082007 | Start Date*: 2008-03-03 | ||||||||||||||||||||||||||
Sponsor Name:Dutch Heart Foundation | ||||||||||||||||||||||||||||
Full Title: A randomised, double blind placebo controlled trial to (A) assess the optimal vitamin K dosage for supplementation, and (B) to access whether complications of anticoagulation treatment will diminis... | ||||||||||||||||||||||||||||
Medical condition: Anti-coagulationtreatment with vitamine K antagonists. | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: NL (Ongoing) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-005967-27 | Sponsor Protocol Number: ASL605LIOM03 PROMET | Start Date*: 2006-10-31 | |||||||||||
Sponsor Name:AZIENDA USL 6 LIVORNO ZONA LIVORNESE | |||||||||||||
Full Title: Study pilot of metronomic chemotherapy with ciclofosfamide, celecoxib and desametasone in patients with diagnosis of carcinoma of the refractory ormon prostate in advanced stage appraisal pharmac... | |||||||||||||
Medical condition: ORMONO REFRACTORY CARCINOMA OF PROSTATE IN ADVANCED STAGE | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-005998-27 | Sponsor Protocol Number: AKF-398 | Start Date*: 2021-03-12 | |||||||||||
Sponsor Name:University of Southern Denmark | |||||||||||||
Full Title: Interleukin-6 inhibitors and drug-drug interactions in patients with Rheumatoid Arthritis. | |||||||||||||
Medical condition: Rheumatoid arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001000-42 | Sponsor Protocol Number: 1144/2020 | Start Date*: 2020-07-09 |
Sponsor Name:Medical University of Vienna | ||
Full Title: The relationship of cholesterol-lowering drugs with steroid HORMONEs, bile acids, vitamin D, the immune system and related diseases such as depression and osteoporosis | ||
Medical condition: Patients with a diagnosed hyperlipidemia treated with statins (with either simvastatin <=20 mg, atorvastatin <=10 mg or rosuvastatin <=10 mg - random allocation), or with atorvastatin >=40 mg or r... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2012-000447-27 | Sponsor Protocol Number: USKH_VL1 | Start Date*: 2012-07-25 |
Sponsor Name:Universitätsklinikum Schleswig-Holstein, Campus Kiel | ||
Full Title: Open Label Study for the Functional Characterization of Drug Metabolism and Transport in patients before routine visceral surgery | ||
Medical condition: Pharmacokinetic trial in patients, with a good general condition before standard abdominal surgery | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Temporarily Halted) | ||
Trial results: (No results available) |
EudraCT Number: 2005-005124-14 | Sponsor Protocol Number: 2005DICPAED | Start Date*: 2007-07-12 | |||||||||||
Sponsor Name:Joint Sponsor: University of Glasgow with NHS greater Glasgow and Clyde [...] | |||||||||||||
Full Title: The unlicensed and off-label use of diclofenac in paediatric patients: Pharmacokinetic, pharmacodynamic and pharmacogenomic evlauations | |||||||||||||
Medical condition: Children undergoing surgery for orthapaedic, ENT, renal or abdominal conditions | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-003311-26 | Sponsor Protocol Number: 77839 | Start Date*: 2021-11-18 |
Sponsor Name:Prinses Máxima Centrum | ||
Full Title: DAVINCY trial: optimal Duration of (fos)aprepitant prophylaxis for nausea and Vomiting INduced by ChemotherapY in children: a double-blind placebo-controlled crossover randomized phase III trial’ | ||
Medical condition: prolonged anti emetic treatment | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: NL (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2011-003118-17 | Sponsor Protocol Number: CRAD001HDE13 | Start Date*: 2011-12-29 | |||||||||||
Sponsor Name:Novartis Pharma GmbH | |||||||||||||
Full Title: A 12 month, multi-center, open-label, randomized, controlled study to evaluate efficacy/safety and evolution of renal function of everolimus in co-exposure with tacrolimus in de novo liver transpla... | |||||||||||||
Medical condition: liver transplantation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-000229-24 | Sponsor Protocol Number: RD.06.SPR.201593 | Start Date*: 2021-02-23 | |||||||||||
Sponsor Name:Galderma S.A. | |||||||||||||
Full Title: An Open-label Drug-Drug Interaction Study to Assess the Effects of Nemolizumab on Cytochrome P450 Substrates in Subjects with Moderate-to-Severe Atopic Dermatitis | |||||||||||||
Medical condition: Moderate-to-severe atopic dermatitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-000641-44 | Sponsor Protocol Number: TailorDose-II | Start Date*: 2017-04-28 | |||||||||||
Sponsor Name:Karolinska intitutet | |||||||||||||
Full Title: TailorDose®-II: Therapeutic dose monitoring of commonly used cytostatic drugs/regimes indicated for breast cancer | |||||||||||||
Medical condition: Newly diagnosed pre- or post-operative breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: SE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-023856-97 | Sponsor Protocol Number: 205MS302 | Start Date*: 2011-09-22 | |||||||||||
Sponsor Name:Biogen Idec Limited | |||||||||||||
Full Title: A Multicenter, Single-Arm, Open-Label, Study to Evaluate the Immunogenicity and Pharmacokinetics of BIIB019, Daclizumab High Yield Process (DAC HYP), Prefilled Syringe Administered by Subcutaneo... | |||||||||||||
Medical condition: Relapsing-remitting Multiple Sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) CZ (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-004436-61 | Sponsor Protocol Number: BRF113771 | Start Date*: 2012-03-30 | |||||||||||
Sponsor Name:GlaxoSmithKline Research and Development Limited | |||||||||||||
Full Title: A Four-Part, Open-Label Study to Evaluate the Effects of Repeat Dose GSK2118436 on the Single Dose Pharmacokinetics of Warfarin, the Effects of Repeat Dose Oral Ketoconazole and Oral Gemfibrozil on... | |||||||||||||
Medical condition: Skin Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-002960-85 | Sponsor Protocol Number: NN20372 | Start Date*: 2008-03-18 | |||||||||||
Sponsor Name:F.Hoffmann-La Roche Ltd | |||||||||||||
Full Title: Randomized, double-blind, placebo-controlled add-on trial of the safety and efficacy of RO4917838 in outpatients on select atypical antipsychotics with prominent negative or disorganized thought sy... | |||||||||||||
Medical condition: Schizophrenia - This study will be conducted to investigate whether or not administration of RO4917838 along with their current antipsychotic regimen to stable patients can lead to further improvem... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) FR (Completed) AT (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-003698-42 | Sponsor Protocol Number: D1250C00012 | Start Date*: 2008-11-21 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A controlled, randomised, double-blind, double-dummy, parallel-group, phase III, multicenter study to evaluate efficacy and safety of the oral direct thrombin inhibitor AZD0837 compared to warfarin... | |||||||||||||
Medical condition: the prevention of stroke and systemic embolic events (SEE) in patients with non-valvular atrial fibrillation (AF) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Prematurely Ended) SK (Completed) DE (Completed) HU (Prematurely Ended) ES (Prematurely Ended) FR (Ongoing) DK (Prematurely Ended) BG (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-014591-21 | Sponsor Protocol Number: H8K-MC-JZAO | Start Date*: 2010-01-18 | |||||||||||
Sponsor Name:Eli Lilly and Company | |||||||||||||
Full Title: A Randomized Phase 3 Study of Tasisulam Administered as an Intravenous Infusion on Day 1 of a 28-Day Cycle vs. Paclitaxel as Second-Line Treatment in Patients with Metastatic Melanoma | |||||||||||||
Medical condition: Second line metastatic melanoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) NL (Prematurely Ended) FR (Completed) ES (Prematurely Ended) GB (Prematurely Ended) FI (Prematurely Ended) PL (Prematurely Ended) IT (Prematurely Ended) AT (Prematurely Ended) BE (Completed) SE (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
